Fresenius Medical Care AG
NYSE:FMS Stok Raporu
Fresenius Medical Care Gelecekteki Büyüme
Future kriter kontrolleri 2/6 Fresenius Medical Care kazanç ve gelirin sırasıyla yıllık 19.3% ve 3.7% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 18% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 7.7% olacağı tahmin edilmektedir.
Anahtar bilgiler Healthcare kazanç büyümesi 20.9% Gelir büyüme oranı 3.7% Gelecekteki özkaynak getirisi 7.7% Analist kapsamı Good
Son güncelleme 06 Nov 2024
Gelecekteki son büyüme güncellemeleri
Fresenius Medical Care AG Confirms Earnings Guidance for the Fiscal Year 2024 Aug 01
Fresenius Medical Care Ag Confirms Earnings Guidance for the Fiscal Year 2024 May 08 Fresenius Medical Care AG Provides Earnings Guidance for Fiscal Year 2024 Feb 20
Fresenius Medical Care AG & Co. Revises Earnings Guidance for the Year 2023
Fresenius Medical Care AG & Co. KGaA Revises Earnings Guidance for the Full Year 2022 Aug 03
Fresenius Medical Care AG & Co. KGaA Provides Earnings Guidance for the Second Half of 2022 Jul 28
Tüm güncellemeleri göster
Fresenius Medical Care AG to Report Q2, 2025 Results on Aug 05, 2025 Nov 05 Fresenius Medical Care AG to Report Q1, 2025 Results on May 06, 2025 Nov 01
Fresenius Medical Care: Let's Look At The Upside Oct 04 Fresenius Medical Care AG to Report Q4, 2024 Results on Feb 25, 2025 Aug 08
Fresenius Medical Care AG Confirms Earnings Guidance for the Fiscal Year 2024 Aug 01
Fresenius Medical Care: Significant Upside Remains Jun 25
Fresenius Medical Care Ag Confirms Earnings Guidance for the Fiscal Year 2024 May 08
Fresenius Medical Care Launches Augmented Reality for Training on Kidney Replacement Therapy Device Mar 19 Fresenius Medical Care AG Appoints Jörg Häring as New Global Head of Legal, Compliance and Human Resources and Also Assume the Role of Labor Director, Effective from June 1, 2024 Mar 13
Broyhill - Fresenius Medical Care: Correctly Focused On Increasing Margins And Returns Feb 23
Fresenius Medical Care AG Proposes Dividend for the Fiscal Year 2023 Feb 21 Fresenius Medical Care AG Provides Earnings Guidance for Fiscal Year 2024 Feb 20
Fresenius Medical Care Brings Dialysis Therapy to Kidney Disease Patients in the U.S Feb 09
Fresenius Medical Care Enters into Favorable Settlement Agreement with U. S. Government Nov 23 Fresenius Medical Care AG & Co. Revises Earnings Guidance for the Year 2023 Fresenius Medical Care AG & Co. KGaA to Report Fiscal Year 2023 Final Results on Mar 22, 2024 Nov 07
An Unknown buyer entered into an agreement to acquire National Cardiovascular Partners, LP from Fresenius Medical Care AG & Co. KGaA (XTRA:FME) Nov 03 Fresenius Medical Care AG & Co. KGaA to Report Q1, 2024 Results on May 07, 2024 Fresenius Medical Care Appoints Craig Cordola as New Management Board Member for Care Delivery Nov 01
Fresenius Medical Care Achieves Key Ai Milestone with First-Phase Completion of Largest Global Dialysis Clinical Dataset Oct 27
Fresenius Medical Care: Don't Let The Ozempic Kidney Failure Scare You Off Oct 12
Fresenius Medical Care Announces Fda Clearance of Versi(R)Hd with Guideme Software Aug 24 An unknown buyer acquired Local dialysis service provider business from Fresenius Medical Care AG & Co. KGaA (XTRA:FME).
Fresenius Medical Care Announces Executive Changes Jul 11
Fresenius Medical Care participated Announces Breakthrough Study Demonstrates That High-Dose Hemodiafiltration Treatment for Kidney Failure Patients Significantly Reduces Mortality Rates Jun 21
Fresenius Medical Care: Other Stocks Still Better, But Upside Exists Jun 01
Fresenius Medical Care Q4 2022 Earnings Preview Feb 21
Fresenius: The Company Is Climbing, And I'm At 'Buy' Jan 06 Fresenius Medical Care AG & Co. KGaA Announces CEO Changes Dec 06
Fresenius Medical Care AG & Co. KGaA, Annual General Meeting, May 16, 2023 Nov 16 Fresenius Medical Care AG & Co. KGaA to Report Q2, 2023 Results on Aug 02, 2023
Fresenius: A Contrarian Opportunity Not Seen For 20 Years (Technical Analysis) Oct 27
Fresenius Medical gains after report of activist Elliott stake in Fresenius SE Oct 19
Fresenius cut to Hold at Jefferies citing staffing issues and inflation Oct 10
Fresenius gets award to provide dialysis services to U.S. military veterans Aug 30
Fresenius appoints head of pharma unit as new CEO Aug 19
Fresenius Medical Care AG & Co. KGaA Revises Earnings Guidance for the Full Year 2022 Aug 03
Fresenius Medical Care: Best Time In 21 Years To Buy This High-Yield Dividend Aristocrat Jul 30
Fresenius Medical Care AG & Co. KGaA Provides Earnings Guidance for the Second Half of 2022 Jul 28
Fresenius Medical Care accused of Medicare fraud in dialysis Jul 13
Fresenius Medical Care AG & Co. KGaA to Report Q3, 2022 Final Results on Nov 09, 2022 May 15
Fresenius: The Upside Is Getting Bigger May 02
Fresenius Medical Care Appoints Nwamaka (Amaka) Eneanya as Head of Strategy and Operations for the Company's Global Medical Office Apr 06
Fresenius Medical Care AG & Co. KGaA Proposes Dividend, Due on 17 May 2022 Apr 01 Fresenius Medical Care Ag & Co. Kgaa Provides Earnings Forecast for the Year 2022
Fresenius Medical Care Reportedly in Talks to Buy Dmed Diyaliz Jan 27
Fresenius Medical Care AG & Co. KGaA Launches New Mobile App to Empower and Engage Nurses Dec 21
You Really Want To Know About Fresenius Medical Care Aug 28
Fresenius Medical Care Approves Dividend for the Fiscal Year 2020 May 21
Fresenius Medical Care Confirms Earnings Guidance for the Fiscal Year 2021 May 07
Fresenius Medical Care AG & Co. KGaA to Report Fiscal Year 2020 Final Results on Mar 23, 2021 Mar 17
Fresenius Medical Care AG & Co. KGaA to Report Q3, 2021 Results on Nov 02, 2021 Feb 24
Fresenius Medical drops 12% on disappointing 2021 outlook Feb 02
Fresenius Medical Care's Frenova Enrolls Patients in Initiative to Build Large Genomic Registry Targeting Kidney Disease Jan 12 Fresenius Medical Care AG & Co. KGaA, Annual General Meeting, May 20, 2021
Fresenius Medical Care EPS beats by €0.06, misses on revenue Oct 29
Fresenius Medical Care AG & Co. KGaA to Report Q1, 2020 Results on May 06, 2020 Sep 30
Fresenius Medical Care AG & Co. KGaA to Report Q2, 2020 Results on Jul 30, 2020 Sep 22
Kazanç ve Gelir Büyüme Tahminleri NYSE:FMS - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (EUR Millions ) Tarih Gelir Kazançlar Serbest Nakit Akışı Faaliyetlerden Nakit Avg. Analist Sayısı 12/31/2026 20,630 1,102 1,878 2,713 16 12/31/2025 19,870 936 1,956 2,562 18 12/31/2024 19,258 676 1,783 2,572 18 9/30/2024 19,239 659 1,538 2,274 N/A 6/30/2024 19,415 530 1,342 2,049 N/A 3/31/2024 19,474 484 1,911 2,613 N/A 12/31/2023 19,454 499 1,918 2,629 N/A 9/30/2023 19,463 450 1,799 2,509 N/A 6/30/2023 19,622 596 1,674 2,407 N/A 3/31/2023 19,554 602 1,401 2,152 N/A 12/31/2022 19,398 673 1,397 2,167 N/A 9/30/2022 19,048 763 1,444 2,237 N/A 6/30/2022 18,393 806 1,444 2,271 N/A 3/31/2022 17,957 878 1,576 2,441 N/A 12/31/2021 17,619 969 1,603 2,489 N/A 9/30/2021 17,372 918 1,477 2,405 N/A 6/30/2021 17,344 998 1,480 2,459 N/A 3/31/2021 17,581 1,131 2,869 3,857 N/A 12/31/2020 17,859 1,164 3,148 4,233 N/A 9/30/2020 18,039 1,330 3,299 4,420 N/A 6/30/2020 18,044 1,309 3,377 4,542 N/A 3/31/2020 17,832 1,212 1,832 3,075 N/A 12/31/2019 17,477 1,200 1,404 2,567 N/A 9/30/2019 17,196 1,282 1,367 2,494 N/A 6/30/2019 16,835 1,234 1,246 2,379 N/A 3/31/2019 16,704 1,974 1,065 2,182 N/A 12/31/2018 16,547 1,982 920 2,062 N/A 9/30/2018 16,676 1,951 766 1,892 N/A 6/30/2018 16,954 1,975 N/A 1,750 N/A 3/31/2018 17,211 1,250 N/A 1,977 N/A 12/31/2017 17,784 1,280 N/A 2,192 N/A 9/30/2017 17,771 1,249 N/A 2,436 N/A 6/30/2017 17,647 1,244 N/A 2,217 N/A 3/31/2017 17,201 1,239 N/A 1,938 N/A 12/31/2016 16,570 1,144 N/A 1,932 N/A 9/30/2016 16,101 1,063 N/A 1,648 N/A 6/30/2016 15,841 998 N/A 1,782 N/A 3/31/2016 15,402 933 N/A 1,491 N/A 12/31/2015 15,455 955 N/A 1,767 N/A 9/30/2015 15,345 939 N/A 1,791 N/A 6/30/2015 15,246 948 N/A 1,914 N/A 3/31/2015 15,428 977 N/A 2,044 N/A 12/31/2014 13,329 864 N/A 1,538 N/A 9/30/2014 12,413 839 N/A 1,476 N/A 6/30/2014 11,112 775 N/A 1,283 N/A 3/31/2014 10,882 791 N/A 1,329 N/A 12/31/2013 10,816 806 N/A 1,478 N/A
Daha fazla göster
Analist Gelecek Büyüme Tahminleri
Kazançlar ve Tasarruf Oranları: FMS 'nin tahmini kazanç büyümesi (yıllık 19.3% ) tasarruf oranının ( 2.6% ) üzerindedir.
Kazançlar ve Piyasa: FMS şirketinin kazançlarının (yıllık 19.3% ) US pazarından (yıllık 15.6% ) daha hızlı büyümesi öngörülüyor.
Yüksek Büyüme Kazançları: FMS şirketinin kazançlarının artması bekleniyor, ancak önemli ölçüde .
Gelir ve Pazar: FMS şirketinin gelirinin (yıllık 3.7% ) US pazarından (yıllık 8.9% ) daha yavaş büyümesi öngörülüyor.
Yüksek Büyüme Geliri: FMS şirketinin gelirinin (yıllık 3.7% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.
Hisse Başına Kazanç Büyüme Tahminleri
Gelecekteki Özkaynak Getirisi
Gelecekteki ROE: FMS 'nin Özsermaye Getirisi 'nin 3 yıl içinde düşük olması tahmin ediliyor ( 7.7 %).
Büyüyen şirketleri keşfedin Simply Wall St™ Simply Wall Street Pty Ltd Level 7, 320 Pitt Street, Sydney Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}